Muroyama R - Search Results

1

[Development status of DAA against hepatitis C].

Kato N, Nakagawa R, Goto K, Muroyama R, Matsubara Y. Kato N, et al. Among authors: muroyama r. Nihon Rinsho. 2015 Dec;73 Suppl 9:262-8. Nihon Rinsho. 2015. PMID: 26845942 Japanese. No abstract available.

2

MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.

Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M. Dharel N, et al. Among authors: muroyama r. Clin Cancer Res. 2006 Aug 15;12(16):4867-71. doi: 10.1158/1078-0432.CCR-06-0111. Clin Cancer Res. 2006. PMID: 16914573

3

Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus.

Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M. Dharel N, et al. Among authors: muroyama r. Hepatology. 2008 Apr;47(4):1136-49. doi: 10.1002/hep.22176. Hepatology. 2008. PMID: 18220274

4

Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients.

Sermasathanasawadi R, Kato N, Muroyama R, Dharel N, Shao RX, Chang JH, Li CZ, Kawabe T, Omata M. Sermasathanasawadi R, et al. Among authors: muroyama r. Liver Int. 2008 Jul;28(6):798-806. doi: 10.1111/j.1478-3231.2008.01725.x. Liver Int. 2008. PMID: 18397234

5

Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication.

Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, Dharel N, Sermsathanasawadi R, Kawabe T, Omata M. Li CZ, et al. Among authors: muroyama r. Liver Int. 2009 Oct;29(9):1413-21. doi: 10.1111/j.1478-3231.2009.02061.x. Epub 2009 Jun 5. Liver Int. 2009. PMID: 19515215 Free PMC article.

6

Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.

Chang JH, Kato N, Muroyama R, Taniguchi H, Guleng B, Dharel N, Shao RX, Tateishi K, Jazag A, Kawabe T, Omata M. Chang JH, et al. Among authors: muroyama r. Liver Int. 2010 Feb;30(2):311-8. doi: 10.1111/j.1478-3231.2009.02144.x. Epub 2009 Oct 16. Liver Int. 2010. PMID: 19840259

7

Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma.

Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Hu Z, et al. Among authors: muroyama r. Cancer Sci. 2009 Dec;100(12):2465-8. doi: 10.1111/j.1349-7006.2009.01338.x. Cancer Sci. 2009. PMID: 20175782 Free PMC article.

8

[New antivirals against hepatitis C virus(protease inhibitors, polymerase inhibitors, and host factor targeting antivirals)].

Kato N, Muroyama R. Kato N, et al. Among authors: muroyama r. Nihon Rinsho. 2011 May;69 Suppl 4:275-81. Nihon Rinsho. 2011. PMID: 22096931 Japanese. No abstract available.

9

[New antivirals against hepatitis C virus].

Kato N, Muroyama R, Goto K. Kato N, et al. Among authors: muroyama r. Nihon Rinsho. 2012 Apr;70(4):664-70. Nihon Rinsho. 2012. PMID: 22568151 Japanese.

10

[Viral hepatitis].

Kato N, Muroyama R, Goto K. Kato N, et al. Among authors: muroyama r. Nihon Rinsho. 2012 Nov;70 Suppl 8:583-8. Nihon Rinsho. 2012. PMID: 23513906 Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters